Skip to main content

Companies researching Ocrevus (ocrelizumab)

Ocrevus (ocrelizumab) is a humanized anti‑CD20 monoclonal antibody employed as an immunosuppressive therapy for multiple sclerosis.

List of companies that research Ocrevus (ocrelizumab)

This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →

CompanyCountryIndustryEmployeesRevenueTechnologies

United States

Higher Education

14k

$2.3B

Ocrevus (ocrelizumab)

United States

Hospitals and Health Care

51

$2M

Ocrevus (ocrelizumab)

Switzerland

Biotechnology Research

108k

$68B

Ocrevus (ocrelizumab)

Australia

Hospitals and Health Care

730

Ocrevus (ocrelizumab)

United States

Hospitals and Health Care

1k

Ocrevus (ocrelizumab)

United Kingdom

Hospitals and Health Care

193k

$105B

Ocrevus (ocrelizumab)

France

Medical Practices

5

Ocrevus (ocrelizumab)

United States

Hospitals and Health Care

1k

$18M

Ocrevus (ocrelizumab)

Germany

Hospitals and Health Care

210

Ocrevus (ocrelizumab)

United States

Biotechnology Research

21k

$26B

Ocrevus (ocrelizumab)

Showing top companies out of 35 that research Ocrevus (ocrelizumab). Get the full list on TheirStack.

Frequently asked questions